USA - New York Stock Exchange - NYSE:RVTY - US7140461093 - Common Stock
The current stock price of RVTY is 110.14 USD. In the past month the price increased by 9.6%. In the past year, price decreased by -6.97%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.1 | 228.09B | ||
| DHR | DANAHER CORP | 30.55 | 166.39B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 193.26 | 58.73B | ||
| A | AGILENT TECHNOLOGIES INC | 26.22 | 41.48B | ||
| IQV | IQVIA HOLDINGS INC | 20.77 | 41.14B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.49 | 30.33B | ||
| WAT | WATERS CORP | 31.03 | 23.46B | ||
| ILMN | ILLUMINA INC | 33.71 | 22.46B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.45 | 19.56B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.55 | 17.14B | ||
| TEM | TEMPUS AI INC | N/A | 11.95B | ||
| CRL | CHARLES RIVER LABORATORIES | 20.76 | 10.78B |
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
REVVITY INC
77 4Th Avenue
Waltham MASSACHUSETTS US
Employees: 11000
Phone: 17816636900
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
The current stock price of RVTY is 110.14 USD. The price increased by 6.02% in the last trading session.
REVVITY INC (RVTY) has a dividend yield of 0.28%. The yearly dividend amount is currently 0.28.
RVTY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
REVVITY INC (RVTY) currently has 11000 employees.
REVVITY INC (RVTY) has a market capitalization of 12.49B USD. This makes RVTY a Large Cap stock.
The outstanding short interest for REVVITY INC (RVTY) is 5.43% of its float.
ChartMill assigns a technical rating of 8 / 10 to RVTY. When comparing the yearly performance of all stocks, RVTY turns out to be only a medium performer in the overall market: it outperformed 55.58% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to RVTY. RVTY scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months RVTY reported a non-GAAP Earnings per Share(EPS) of 4.79. The EPS increased by 1.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.44% | ||
| ROA | 1.96% | ||
| ROE | 3.22% | ||
| Debt/Equity | 0.36 |
26 analysts have analysed RVTY and the average price target is 114.85 USD. This implies a price increase of 4.28% is expected in the next year compared to the current price of 110.14.
For the next year, analysts expect an EPS growth of 2.34% and a revenue growth 3.27% for RVTY